NCT06665295 (THRIVE-CAR-T) is a NA clinical trial of THRIVE-CAR-T in CAR T-Cell Therapy, sponsored by Patrick C. Johnson, MD.

Who is sponsoring NCT06665295?

NCT06665295 is sponsored by Patrick C. Johnson, MD.

What drugs are being tested in NCT06665295?

Interventions in NCT06665295: THRIVE-CAR-T.

What condition does NCT06665295 study?

NCT06665295 studies CAR T-Cell Therapy.

Is NCT06665295 still recruiting?

NCT06665295 is currently recruiting now. Last updated 1 April 2026.

Last reviewed 2026-04-01 · How we verify

NCT06665295: THRIVE-CAR-T

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

THRIVE-CAR-T Digital App

Recruiting now NA Last updated 1 April 2026

What this trial tests

NA trial testing THRIVE-CAR-T in CAR T-Cell Therapy in 100 participants. Currently enrolling.

Timeline

17 October 2024

Primary endpoint
1 November 2026

31 December 2026

Quick facts

Lead sponsor	Patrick C. Johnson, MD
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	100
Start date	17 October 2024
Primary completion	1 November 2026
Estimated completion	31 December 2026
Sites	1 location across United States

Drugs / interventions tested

THRIVE-CAR-T

Conditions studied

CAR T-Cell Therapy — all drugs for CAR T-Cell Therapy →

Sponsor

Patrick C. Johnson, MD

Who can join

18 and older, any sex, with CAR T-Cell Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to learn if a digital mobile application called THRIVE-CAR-T is helpful for the care of patients undergoing CAR-T cell therapy. The main question\[s\] it aims to answer are whether the THRIVE-CAR-T app is feasible and acceptable to patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for CAR T-Cell Therapy

Currently open trials in the same condition.

NCT05354973 — ePRO for the Timely Detection of Side Effects in Cancer Patients Undergoing CAR T Immunotherapy · recruiting
NCT06643221 — Exercise as an Immune Adjuvant for Allogeneic Cell Therapies · EARLY_PHASE1 · recruiting

Other Patrick C. Johnson, MD trials

Trials by the same sponsor.

NCT05583149 — Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06665295 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Patrick C. Johnson, MD
Last refreshed: 1 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06665295.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing